CSF2 and neoplasm: The expression of CXCL1, CXCL2, CXCL5, and CXCL8, which are CXCR2 ligands, and the expression of KITL and GM-CSF are strongly enhanced by KRAS signaling in cancer cells and tumor-derived hypoxia (73).